An exhausted child may stop wheezing because airflow is critically reduced. Mental-status change, poor air entry, silent chest, or a normal/rising carbon dioxide level despite ongoing distress is ominous. Begin inhaled short-acting bronchodilator and oxygen when needed, add ipratropium for a significant exacerbation, and give systemic steroid early. Metered-dose inhaler with a spacer is effective when technique and cooperation are adequate; nebulization is useful when severe distress or oxygen delivery requires it. Routine chest radiography is unnecessary unless the pattern suggests pneumonia, pneumothorax, foreign body, or another diagnosis.72
Verified acute-asthma dose anchors: children older than 1 year
The CPS medication table gives nebulized albuterol 2.5 mg if <20 kg or 5 mg if ≥20 kg, repeated according to severity and response. For initial combined therapy, nebulized ipratropium 250 micrograms, up to three doses in the first hour, is an option; 500 micrograms may be used at ≥30 kg. Oral prednisone/prednisolone is 1–2 mg/kg, maximum 50 mg, with the course determined by the acute plan. In severe incomplete response, monitored IV magnesium 40–75 mg/kg over 20–30 minutes, maximum 2.5 g, is a specialist escalation. Verify concentration, route, age, and local protocol before administering.73
Persistent severe distress after initial treatment requires continuous bronchodilator consideration, IV magnesium, critical-care involvement, and evaluation for complications. Beta-agonists can produce tachycardia, tremor, hypokalemia, and lactate elevation; persistent tachypnea with improved wheeze may therefore require assessment rather than reflexively escalating albuterol forever. Discharge requires sustained clinical improvement and a feasible home interval between rescue doses, not just one temporarily better examination.72
Long-term control is a separate decision from acute rescue. Confirm the diagnosis when age permits, assess symptom and exacerbation risk, check adherence and inhaler technique, and reduce smoke/allergen exposure. GINA favors ICS-containing treatment rather than relying on SABA alone in school-age children and adolescents; the age-specific preferred regimen, device, and authorized product matter. An adolescent’s adult-style ICS-formoterol strategy should not be copied into a preschool plan. Every significant exacerbation is an opportunity for an action plan, controller review, school access, and timely follow-up.70